The Abu Dhabi Biobank has entered a strategic collaboration with pharmaceutical giant AstraZeneca to strengthen clinical research and accelerate precision medicine in the region. The partnership combines the Biobank’s extensive biospecimen repository, genomic data, and population-level datasets with AstraZeneca’s expertise across multiple therapeutic areas.
The alliance will focus on biomarker discovery, pharmacogenomics, and real-world evidence generation, with an emphasis on addressing diseases within Middle Eastern populations. Both organizations aim to translate complex biological insights into personalized healthcare solutions, supporting Abu Dhabi’s ambition to become a global hub for life sciences innovation and data-driven medical research.
